文献速递前列腺癌

LUNAR:177镥-PSMA新辅助联合消融性放疗治疗寡复发前列腺癌的随机2期研究(临床试验方案)

LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol).
PubMed 文献 · BJU Int · 2023-03-02

LUNAR是一项开放标签、随机、分层、两臂、单中心2期试验,计划入组100例寡复发转移性激素敏感性前列腺癌(mHSPC)患者,按1:1随机接受177Lu-PNT2002新辅助联合立体定向体部放疗(SBRT)或单纯SBRT,主要终点为无进展生存期。

要点

  • 试验入组1-5个PSMA PET/CT病灶且经中心复核的寡复发mHSPC患者。
  • 实验组接受两周期177Lu-PNT2002(6.8 GBq)后行剂量适配SBRT。
  • 主要终点为无进展生存期,2022年9月开始入组。

核心结论

  • 在单纯转移灶定向治疗基础上加用177Lu-PNT2002可能进一步延缓疾病进展。
  • 该2期试验结果将首次以随机方式确定177Lu-PNT2002联合SBRT在寡复发mHSPC患者中的附加获益。

研究设计与样本

  • 开放标签、随机、分层、两臂、单中心2期试验,计划入组100例寡复发mHSPC患者,按1:1随机分组。
  • 关键入选标准包括PSMA PET/CT发现1-5个病灶且经委员会认证的核医学医师中心复核。
  • 关键排除标准包括去势抵抗性疾病、新发寡转移性疾病及入组前6个月内接受雄激素剥夺治疗(ADT)。

主要发现

  • 对照组接受针对所有疾病部位的SBRT。
  • 实验组接受两周期新辅助177Lu-PNT2002(6.8 GBq),间隔6-8周,随后4-6周行PSMA PET/CT,1-2周后行剂量适配SBRT。
  • 主要终点为无进展生存期;次要终点包括影像学和前列腺特异性抗原进展、急性和晚期医生评分毒性、患者报告生活质量、无ADT生存期、进展时间、总生存期、局部区域控制和缓解持续时间。
  • 研究于2022年9月开始入组。

关键数值与推荐

  • 实验组177Lu-PNT2002剂量为6.8 GBq,两周期,间隔6-8周。
  • 实验组在177Lu-PNT2002后4-6周行PSMA PET/CT,1-2周后行SBRT。
  • 计划入组100例患者,按1:1随机分配。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy of 177 Lu-PNT2002, a novel radiolabelled small molecule that binds with high affinity to prostate-specific membrane antigen (PSMA), in combination with stereotactic body radiotherapy (SBRT) to all sites of metastasis, vs SBRT alone, in men with oligorecurrent metastatic hormone-sensitive prostate cancer (mHSPC). PATIENTS AND METHODS: The 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR) trial is an open-label, randomized, stratified, two-arm, single-centre, Phase 2 trial to compare the efficacy and safety of neoadjuvant 177 Lu-PNT2002 plus SBRT vs SBRT alone in men with oligorecurrent mHSPC. Key eligibility criteria include one to five lesions identified on a PSMA positron emission tomography (PET)/computed tomography (CT) scan centrally reviewed by a board-certified nuclear medicine physician. Key exclusion criteria include castrate-resistant disease, de novo oligometastatic disease and receipt of androgen deprivation therapy (ADT) within 6 months of trial enrolment. The trial aims to enrol 100 patients who will be centrally randomized to one of the two treatment arms, in a 1:1 ratio. Patients in the control arm receive SBRT to all sites of disease. Patients in the experimental arm receive two cycles of neoadjuvant 177 Lu-PNT2002 (6.8 GBq) 6-8 weeks apart, followed by an interval PSMA PET/CT in 4-6 weeks and dose-adapted SBRT to all sites of disease 1-2 weeks later. The primary endpoint is progression-free survival. Secondary endpoints are radiographic and prostate-specific antigen-based progression, acute and late physician-scored toxicity, patient-reported quality of life, ADT-free survival, time to progression, overall survival, locoregional control, and duration of response. Enrolment in the study commenced in September 2022. RESULTS AND CONCLUSIONS: The addition of 177 Lu-PNT2002 to metastasis-directed therapy alone may potentially further forestall disease progression. The results of this Phase 2 trial will determine, for the first time in a randomized fashion, the added benefit of 177 Lu-PNT2002 to SBRT in patients with oligorecurrent mHSPC.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Ma TM, Czernin J, Felix C, et al. LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol). BJU Int. 2023. PMID: 36797449. doi:10.1111/bju.15988

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。